Biosimilars as a CEO-Level Business Strategy
The biosimilars market has evolved from a niche regulatory category into a strategically significant segment of the global pharmaceutical industry. With more than $300 billion worth of biologic therapies facing patent expiration through 2030, the market opportunity for biosimilar developers is substantial. At the same time, the operational complexity of developing, manufacturing, and commercializing biosimilars exceeds that of small-molecule generics by an order of magnitude.
CEOs leading biosimilar companies, or pharmaceutical companies with biosimilar portfolios, face a distinctive operational challenge: they must achieve the scientific rigor of a novel biologic developer, the manufacturing precision of a biologics contract manufacturer, the regulatory sophistication to navigate a complex and evolving approval framework, and the commercial agility to compete in markets shaped by payer dynamics, physician behavior, and innovator defensive strategies.
This article examines the operational frameworks that enable CEOs to build successful biosimilar businesses across the development, manufacturing, regulatory, and commercial dimensions.
Understanding the Biosimilar Development Framework
Biosimilars are not generic drugs. They are highly similar versions of previously approved biologic medicines, demonstrated through an extensive comparability exercise that encompasses analytical, preclinical, and clinical evidence. The regulatory pathway reflects this complexity.
Analytical characterization as the foundation. The biosimilar development process begins with analytical characterization of the reference product and the proposed biosimilar across multiple attributes: primary structure, higher-order structure, biological activity, impurity profile, and stability. The quality of this analytical work determines the efficiency of everything that follows. CEOs who invest in high-quality analytical capabilities, whether internal or through partners, build a foundation that reduces downstream development risk and regulatory uncertainty.
Regulatory pathway options. In the United States, biosimilars are approved under the 351(k) pathway, which can lead to either biosimilar approval or interchangeability designation. The interchangeability designation, which allows pharmacist-level substitution without prescriber intervention in most states, requires demonstration of switching studies. CEOs must evaluate whether the commercial value of interchangeability justifies the additional investment for each specific product and market.
Extrapolation strategy. Biosimilar developers can often seek approval for indications of the reference product beyond those specifically studied in clinical trials, through a process called extrapolation. Regulatory agencies assess whether the mechanism of action, patient population, and safety profile support extrapolation from studied to unstudied indications. A well-designed extrapolation strategy can dramatically expand the commercial opportunity of a biosimilar program with incremental development investment.
Reference product selection. Not every biologic with an expiring patent is an equally attractive biosimilar target. CEOs and their development teams should evaluate targets across multiple dimensions: market size and growth, technical complexity of development, manufacturing accessibility, competitive landscape, payer dynamics, and patent situation. Selecting the right reference product targets is among the most consequential strategic decisions a biosimilar CEO makes.
Manufacturing Operations for Biosimilars
Biologic manufacturing is among the most complex and capital-intensive operations in the pharmaceutical industry. Biosimilar manufacturers face the additional challenge of producing a product highly similar to a reference biologic that was itself developed and manufactured under proprietary conditions.
Cell line development and manufacturing process. The cell line expressing the biosimilar protein and the manufacturing process parameters are proprietary to the developer and cannot replicate the innovator’s process exactly. This means biosimilar manufacturers must develop their own cell lines and processes while demonstrating that the resulting molecule is highly similar to the reference product analytically and biologically. Cell line development and process optimization are major investments that typically take two to three years before reaching clinical manufacturing.
Scale and technology platform. CEOs must decide whether to build internal manufacturing capabilities, rely on contract development and manufacturing organizations, or pursue a hybrid model. Building internal biologics manufacturing is a capital commitment of hundreds of millions of dollars with a multi-year lead time. CDMOs can provide speed and flexibility but introduce supply chain dependency and technology transfer risk. The right model depends on the company’s scale, product portfolio, and strategic horizon.
Quality systems for biologics. Biosimilar manufacturing quality systems must meet the same standards as innovator biologics. Given the natural variability inherent in biological systems, maintaining product consistency across batches, over time, and through process changes requires robust analytical monitoring, statistical process control, and a quality culture that extends from the CEO to the manufacturing floor. Regulatory agencies scrutinize biosimilar manufacturing quality closely, and deficiencies in this area have derailed multiple programs.
Supply chain resilience. The COVID-19 pandemic exposed critical vulnerabilities in biopharmaceutical supply chains. Biosimilar CEOs should conduct systematic supply chain risk assessments covering raw material sourcing, critical consumable availability, and manufacturing redundancy. For reference product supply needed for comparability and switching studies, contracts and supply agreements require careful management.
For a comprehensive review of the operational systems that underpin biosimilar development and commercialization, the pharma operations checklist provides a structured reference across all functional areas.
Regulatory Strategy for Biosimilar CEOs
The biosimilar regulatory landscape is both more structured and more dynamic than innovator regulatory pathways. Structured, because the comparability exercise framework provides clear evidentiary standards. Dynamic, because policies on interchangeability, naming, labeling, and substitution continue to evolve in the United States and globally.
Building regulatory intelligence capabilities. CEOs should invest in regulatory intelligence functions that monitor policy developments across major markets in real time. Regulatory policy changes, such as FDA guidance updates on interchangeability requirements or European Medicines Agency biosimilar guideline revisions, can materially affect development plans and commercial strategies. Real-time awareness allows the organization to adapt rather than react.
Managing reference product supply for comparability. Biosimilar approval requires extensive analytical comparability studies using the reference product. Managing reference product procurement, including sourcing from multiple markets where different manufacturing batches may be available, is an operational function that requires early planning and significant logistical coordination.
Patent litigation as a strategic consideration. The Biologics Price Competition and Innovation Act in the United States established a specific patent dispute resolution process (the “patent dance”) that creates significant legal risk and complexity for biosimilar developers. CEOs must ensure robust legal operations to navigate patent litigation, freedom-to-operate assessments, and the timing decisions that follow from litigation outcomes.
Naming, labeling, and substitution policies. FDA policies on biosimilar nonproprietary naming (which biosimilars carry a four-letter suffix appended to the reference product’s name) and pharmacist substitution conditions continue to evolve. These policies have commercial implications: substitutability at the pharmacy level can significantly affect uptake dynamics. CEOs should monitor and engage with policy development in this area.
Commercial Operations in a Competitive Biosimilars Market
Commercial operations for biosimilars require a fundamentally different model than either innovator biologics or small-molecule generics. The biosimilar commercial environment is defined by payer leverage, formulary management, innovator defensive contracting, and physician confidence challenges.
Payer and formulary strategy. In the United States, payers and pharmacy benefit managers have become the primary lever for biosimilar market access. Exclusive or preferred formulary positioning, which payers grant in exchange for rebates and pricing concessions, can drive market share more effectively than physician detailing. CEOs must build or access managed care contracting expertise capable of competing in this environment.
Innovator defensive strategies. Innovator manufacturers have deployed sophisticated strategies to retain market share in the face of biosimilar competition, including patient assistance programs that shift patient cost-sharing dynamics, long-term payer contracts with anti-substitution provisions, and authorized biosimilar launches at near-biosimilar pricing. CEOs should model competitive scenarios that account for innovator defensive moves before committing to development investments.
Physician confidence building. Despite regulatory approval and extensive evidence of biosimilarity, some physicians maintain uncertainty about biosimilars, particularly for immunology and oncology products. Medical affairs operations that engage with clinical thought leaders, support peer-to-peer education, and provide scientific exchange on biosimilar evidence play an important role in building physician confidence. This is not a commercial activity. It is a scientific communication function.
Hospital and institutional channel. Hospitals and health systems are often the most accessible commercial channel for biosimilars, particularly for infusible and injectable products. Pharmacy and therapeutics committees can evaluate biosimilars on evidence and cost-effectiveness criteria, creating a more straightforward adoption pathway than the physician-by-physician sales model. CEOs should ensure their commercial models prioritize the institutional channel where applicable.
According to McKinsey analysis of the global biosimilars market, companies that build integrated commercial and payer access strategies, rather than treating them as sequential functions, achieve faster market penetration and more durable market share. The implication for CEOs is that commercial and market access capabilities must be built together, not in sequence.
Pricing Strategy and Value Demonstration
Biosimilar pricing is a more nuanced exercise than small-molecule generic pricing. Small-molecule generics compete primarily on price, often reaching 80-90% discounts to the innovator within months of market entry. Biosimilar pricing dynamics are different because of lower competition density (fewer biosimilar entrants per reference product), higher manufacturing costs, and the role of payer rebating in determining effective net pricing.
List price versus net price. Biosimilar CEOs must build financial models that distinguish clearly between list price and net price after rebates. In heavily rebated markets like U.S. immunology, the effective net price may be significantly below list price, and competitive positioning on net price is the actual commercial battlefield.
Value-based contracting. As payers increasingly seek outcomes-based payment arrangements, biosimilar manufacturers have both an opportunity and a challenge. The opportunity is to differentiate through outcomes commitments in markets where innovators cannot credibly offer them. The challenge is that outcomes-based contracts require robust real-world data infrastructure to execute.
Global pricing consistency. Biosimilar pricing in different markets creates international reference pricing risks that CEOs must manage. A significant price concession in one country can affect negotiations and political pressure in others. Global pricing strategy requires coordination across commercial, market access, and finance functions.
Building the Right Leadership Team
Biosimilar development requires a blend of technical, regulatory, and commercial talent that is not easily found in single individuals. CEOs building biosimilar companies need leadership teams that combine strengths across analytical chemistry and biophysics, biologics manufacturing, regulatory affairs, and specialty biologic commercial operations.
The pharma portfolio management discipline is particularly relevant for biosimilar CEOs managing multiple programs simultaneously, where capital allocation decisions across a portfolio of candidates require rigorous assessment of technical risk, competitive dynamics, and commercial potential.
Conclusion
Building a successful biosimilar business requires operational capabilities that span the full pharmaceutical value chain, from analytical development through commercial execution, with exceptional depth at every stage. The margin for error is narrow: technical failures are expensive, regulatory setbacks are time-consuming, and commercial missteps in a competitive market are difficult to reverse.
CEOs who build biosimilar businesses with this operational depth, investing in manufacturing excellence, regulatory sophistication, and market access expertise, position their companies to capture meaningful share of one of the largest pharmaceutical market opportunities of the coming decade.
The patients who depend on affordable access to life-changing biologic therapies are waiting for these companies to succeed.
Related Reading
For further context, explore Pharma CEO Business Operations Checklist and Allergy Portfolio Pharma CEO Business Operations: Strategic Execution Guide.